Endogen HP Warnings

Urofollitropin (Endogen HP) drug should only be used by physicians who are thoroughly familiar with infertility problems.
Overstimulation of the Ovary During Urofollitropin (Endogen HP) Therapy: Ovarian Enlargement: Mild to moderate uncomplicated ovarian enlargement which may be accompanied by abdominal distension and/or abdominal pain occurs in susceptible individuals treated with follitropin and hCG, and generally regresses without treatment within two or three weeks. In order to minimize the hazard associated with the occasional abnormal ovarian enlargement, which may occur with FSH-hCG therapy, the lowest dose consistent with expectation of good results should be used.
Careful monitoring of ovarian response can further minimize the risk of over stimulation. If the ovaries are abnormally enlarged on the last day of Urofollitropin (Endogen HP) therapy, hCG should not be administered in the course of therapy; this will reduce the chances of development of the Ovarian Hyperstimulation Syndrome. If severe OHSS occurs, treatment must be stopped and the patient should be hospitalized.
Multiple Pregnancies: Multiple pregnancies have occurred following treatment with Urofollitropin (Endogen HP) SC and IM. The patient and her partner should be advised of the potential risk of multiple births before starting treatment.
Hypersensitivity/ Anaphylactic Reactions: Hypersensitivity/anaphylactic reactions associated with follitropins for injection, have been reported in some patients.